X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Paxzen (nirmatrelvir) is an oral protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxzen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
Paxlovid (Nirmatrelvir) is an oral protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
With this agreement, the active pharmaceutical ingredient nirmatrelvir can be fully manufactured in Brazil by Nortec, ensuring safety and adherence to treatment for countries such as: South Africa, Tanzania, Venezuela, Bolivia, Ethiopia, Haiti, Honduras, among others.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Nirmatrelvir-Generic
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Medicines Patent Pool
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 22, 2022
Details:
Under the agreement, Pfizer will commercialize Paxlovid (nirmatrelvir with ritonavir), the first oral antiviral pill approved by the U.S. Food and Drug Administration, for the treatment of privately insured commercial patients with prices to be negotiated with payers.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 13, 2023
Details:
The partnership aims to launch a local brand of the Covid-19 oral therapeutic treatment Paxlovid (nirmatrelvir/ritonavir) in an attempt to improve the access for treatment in China.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 29, 2023
Details:
Paxlovid (nirmatrelvir tablets and ritonavir tablets) is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV-2 3CL protease inhibitor) therapy. It is being developed for the treatment of long COVID-19 in adults.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Paxlovid™ (nirmatrelvir tablets and ritonavir tablets) is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV-2 3CL protease inhibitor) therapy. It is being developed for the treatment of long COVID-19 in adults.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Paxlovid™ (nirmatrelvir tablets and ritonavir tablets) is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV-2 3CL protease inhibitor) therapy. It is being developed for the treatment of mild-to-moderate COVID-19 in adults.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
Hetero’s ‘NIRMACOM’ (nirmatrelvir), a generic version of Pfizer’s COVID-19 oral antiviral drug ‘PAXLOVID’ is co-packaged with ritonavir tablets. The combi pack, launched by Hetero as NIRMACOM, will contain nirmatrelvir 150 mg (2 tablets) and ritonavir 100mg (1 tablet).
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Nirmacom
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2022
Details:
Paxlovid (ritonavir) is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV-2 3CL protease inhibitor) therapy. It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness.
Lead Product(s): Ritonavir,Nirmatrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 14, 2022
Details:
Paxlovid (Nirmatrelvir) is an oral antiviral pill that can be taken at home to help keep high-risk patients from getting so sick that they need to be hospitalized for treatment of COVID-19.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
Zenara said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatment of mild-to-moderate Covid-19 in adults.
Lead Product(s): Ritonavir,Nirmatrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxzen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
After finding Paxlovid (nirmatrelvir), subject initiated supplementation with the 3CL protease inhibitor immune support dietary supplement Tollovid. Tollovir is an oral 3CL protease inhibitor and anti-cytokine therapeutic candidate.
Lead Product(s): Nirmatrelvir,Ritonavir,Plant Extracts
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2022
Details:
The unique enzyme is an important element in the manufacture of PAXLOVID™ (ritonavir) and plays a role in supporting the efforts to ensure rapid availability of this COVID-19 oral treatment to people around the world.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 14, 2022
Details:
Final results from EPIC-HR study showed an 86% reduction in relative risk of hospitalizations or death from any cause; no deaths were observed in patients treated with PAXLOVID™ (nirmatrelvir [PF-07321332] tablets through Week 24, compared to 15 deaths observed with placebo.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations.
Lead Product(s): Ritonavir,Nirmatrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
In the EPIC-SR study of PAXLOVID™(nirmatrelvir [PF-07321332] tablets and ritonavir tablets), the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met.
Lead Product(s): Ritonavir,Nirmatrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
Paxlovid (nirmatrelvir) is an orally bioavailable protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Indian Council of Medical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2022
Details:
In this trial, compared to placebo, Pfizer observed risk reductions of 32% and 37% in adults who received PAXLOVID for five and ten days, respectively, to prevent infection.
Lead Product(s): Ritonavir,Nirmatrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
India's drug regulator approved antiviral medication Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for restricted emergency use against Covid-19 amid rising infections in the country.
Lead Product(s): Ritonavir,Nirmatrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hetero Drugs
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2022
Details:
Ritonavir oral tablet approved by China NMPA, is a component of oral direct-acting antiviral drug Paxlovid (Nirmatrelvir+ritonavir), an antiviral protease inhibitors for the treatment of COVID19.
Lead Product(s): Ritonavir,Nirmatrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2022
Details:
The agreement aims to commercialize a generic version of Pfizer’s COVID-19 oral treatment, Paxlovid (nirmatrelvir and ritonavir), indicated for the treatment of mild-to-moderate coronavirus disease, in 95 low and middle-income markets.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Strides Pharma Science
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 21, 2022
Details:
Sublicences will allow manufacturers (Teva, Cipla, Biocon, Amneal, Viatris, Torrent, MSN, Sun Pharma, Cadila, Glenmark, Fosun, Beximco, Celltrion & others) to produce the raw materials for generic of Pfizer’s COVID-19 nirmatrelvir and finished drug co-packaged with ritonavir.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Nirmatrelvir-Generic
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 17, 2022
Details:
Clinical data from EPIC-HR study showed PAXLOVID, (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) reduced risk of hospitalization or death from any cause by 89% and 88% compared to placebo, with no deaths observed in treatment group for COVID-19 patients.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of COVID-19 in adults, is administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
Details:
Taken together, these in vitro studies suggest that PAXLOVID has the potential to maintain plasma concentrations many-fold times higher than the amount required to prevent Omicron from replicating in cells.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2022
Details:
PAXLOVID includes nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer’s laboratories, which was specifically designed to block the activity of the SARS-CoV-2 Mpro, an enzyme that the coronavirus needs to replicate.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2022
Details:
PAXLOVID is an investigational SARS-CoV-2 protease inhibitor antiviral therapy. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2021
Details:
CHMP based their advice on positive results from Phase 2/3 EPIC-HR, where data demonstrated 89% reduction in risk of COVID-19-related hospitalization or death in patients treated with PAXLOVID tablet (nirmatrelvir and ritonavir), and also initiated rolling submission with EMA.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
Details:
The result showing PAXLOVID (Nirmatrelvir) significantly reduced the risk of hospitalization or death for any cause by 89% compared to placebo in non-hospitalized, high-risk adult patients with COVID-19 treated within three days of symptom onset.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
Under the terms of license agreement between Pfizer and MPP, qualified generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply PF-07321332 in combination with ritonavir to 95 countries, covering up to approx 53% of the world’s population.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 16, 2021
Details:
The submission to the USFDA includes clinical data from the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) interim analysis. Rolling submission of non-clinical data for PAXLOVID was initiated with the U.S. FDA in October 2021.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
PAXLOVID™ is an investigational SARS-CoV-2 protease inhibitor antiviral therapy, specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure, potentially helping patients avoid severe illness.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2021
Details:
PF-07321332 is an investigational SARS-CoV-2-3CL protease inhibitor antiviral therapy, specifically designed to be administered orally. PF-07321332 is co-administered with a low dose of ritonavir, for the prevention of COVID-19 infection.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: PF-07321332
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2021
Details:
The oral antiviral clinical candidate PF-07321332, a SARS-CoV2-3CL protease inhibitor, has shows potent in vitro anti-viral activity against coronaviruses, suggesting potential for use in the treatment of COVID 19 and potential use to address future coronavirus threats.
Lead Product(s): Nirmatrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: PF-07321332
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
